Feasibility and ethical issues: experiences and concerns of healthcare workers regarding a new RSV prophylaxis programme in Nunavik, Quebec

Feasibility and ethical issues: experiences and concerns of healthcare workers regarding a new RSV prophylaxis programme in Nunavik, Quebec

Background: The respiratory syncytial virus (RSV) is a major cause of hospitalisation in young Inuit children. Prophylaxis with palivizumab is routinely recommended for premature infants and those with severe pulmonary or cardiac diseases. In the fall 2016, the Quebec Ministry of Health expanded the...

Full description

Bibliographic Details
Main Authors:	Armelle Lorcy, Rodica Gilca, Eve Dubé, Marie Rochette, Gaston De Serres
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2020-01-01
Series:	International Journal of Circumpolar Health
Subjects:	respiratory syncytial virus palivizumab health-care workers experiences opinions inuit health services
Online Access:	http://dx.doi.org/10.1080/22423982.2020.1742564

Similar Items

Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada
by: Rodica Gilca, et al.
Published: (2020-12-01)

Effects of palivizumab prophylaxis on respiratory syncytial virus (RSV) infections in Montenegro
by: Envera Lekic, et al.
Published: (2024-05-01)

A CLINICAL AND ECONOMICAL ANALYSIS OF THE RESULTS PRODUCED BY THE PROGRAM OF RSV-INFECTION PROPHYLAXIS DURING THE EPIDEMIOLOGICAL SEASON OF 2012/2013 IN MOSCOW
by: V. I. Ignat'eva, et al.
Published: (2013-11-01)

The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence
by: Antonino Capizzi, et al.
Published: (2017-08-01)

Adherence to Palivizumab for Respiratory Syncytial Virus Prophylaxis in Romanian Infants
by: Andreea Calomfirescu-Avramescu, et al.
Published: (2025-02-01)

Cervical cancer screening preference among Inuit women in Nunavik, Quebec
by: Gabrielle Gosselin, et al.
Published: (2024-12-01)

RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study
by: Ruomei Xu, et al.
Published: (2020-10-01)

Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study
by: Chiara Ratti, et al.
Published: (2023-01-01)

Wild fish consumption and latitude as drivers of vitamin D status among Inuit living in Nunavik, northern Québec
by: Matthew Little, et al.
Published: (2024-01-01)

Increasing our knowledge about the epidemiology of Helicobacter pylori in Nunavik’s Inuit population (Québec, Canada) using Qanuilirpitaa? 2017 cross-sectional survey
by: Julie Ducrocq, et al.
Published: (2024-12-01)

Palivizumab prophylaxis of RSV infections in Bosnia and Herzegovina
by: Suada Heljic, et al.
Published: (2016-02-01)

RSV Disease Threat and Innovative Prevention Methods in Health Protection: A Review
by: Paulina Dąbrowska, et al.
Published: (2024-02-01)

Cost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan
by: Naruhiko Ishiwada, et al.
Published: (2024-06-01)

A post-incorporation study on the use of palivizumab in the Brazilian public health system
by: Joanna d’Arc Lyra Batista, et al.
Published: (2021-01-01)

Palivizumab e virus respiratorio sinciziale: una panoramica
by: Paolo Manzoni
Published: (2011-07-01)

Patient equity and respiratory syncytial virus Immunoprophylaxis
by: H. Cody Meissner
Published: (2019-01-01)

Bronchiolitis - diagnostic and therapeutic difficulties in pediatric patients
by: Iwona Kowalska, et al.
Published: (2020-03-01)

Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016–2017 epidemic season: a systematic review of seven Italian reports
by: Renato Cutrera, et al.
Published: (2019-11-01)

Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29–34 6/7 weeks' gestation in the United States
by: Tianzhou Yu, et al.
Published: (2024-03-01)

Impact of pneumococcal vaccines use on invasive pneumococcal disease in Nunavik (Quebec) from 1997 to 2010
by: Jean-Baptiste Le Meur, et al.
Published: (2014-01-01)

Regional impact of prophylaxis with the monoclonal antibody palivizumab on ospitalizations from respiratory syncytial virus in infants
by: Swiss Medical Weekly
Published: (2001-03-01)

Update to: Study Pre-protocol for “BronchStart - The Impact of the COVID-19 Pandemic on the Timing, Age and Severity of Respiratory Syncytial Virus (RSV) Emergency Presentations; a Multi-Centre Prospective Observational Cohort Study” [version 3; peer review: 2 approved]
by: Mark D. Lyttle, et al.
Published: (2024-10-01)

Epitope-Specific Serological Assays for RSV: Conformation Matters
by: Emily Phung, et al.
Published: (2019-02-01)

Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006–2010
by: Jesse Papenburg, et al.
Published: (2012-01-01)

Update to: Study Pre-protocol for “BronchStart - The Impact of the COVID-19 Pandemic on the Timing, Age and Severity of Respiratory Syncytial Virus (RSV) Emergency Presentations; a Multi-Centre Prospective Observational Cohort Study” [version 4; peer review: 3 approved, 1 approved with reservations]
by: Mark D. Lyttle, et al.
Published: (2024-12-01)

Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab
by: Mariana Bueno Manini, et al.

Prevention of respiratory syncytial virus infection in children. Recommendations of the Polish Society of Paediatrics and the National Paediatric Consultant
by: Teresa Jackowska, et al.
Published: (2024-12-01)

Effect of an In-Home Palivizumab Administration Program for Children with Medical Complexity
by: Hina Emanuel, et al.
Published: (2024-09-01)

Significations accordées par des jeunes et des enseignants inuit à leur vécu familial, scolaire et communautaire au Nunavik
by: Tatiana Garakani
Published: (2016-10-01)

Lead exposure in Nunavik: from research to action
by: Ariane Couture, et al.
Published: (2012-07-01)

One‐year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America
by: Leandro Martin Castillo, et al.
Published: (2017-09-01)

Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation
by: D Wang, et al.
Published: (2008-12-01)

Suicides in Nunavik: a life course study
by: William Affleck, et al.
Published: (2021-01-01)

Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection
by: Hasindu S. Edirisinghe, et al.
Published: (2023-11-01)

Respiratory syncytial virus seasonality in Brazil: implications for the immunisation policy for at-risk populations
by: André Ricardo Ribas Freitas, et al.
Published: (2016-01-01)

Respiratory syncytial virus outbreak in neonatal intensive care unit: Impact of infection control measures plus palivizumab use
by: Silva Camila de A, et al.
Published: (2012-05-01)

Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil
by: Roseane Porfírio de Souza, et al.
Published: (2019-08-01)

Être avec les rivières : regard inuit (Nunavik, Canada)
by: Laine Chanteloup, et al.
Published: (2023-12-01)

Socio-demographic and substance use characteristics of unintentional injuries among Nunavik youth
by: Emilie Beaulieu, et al.
Published: (2022-12-01)

Middle ear abnormalities at age 5 years in relation with early onset otitis media and number of episodes, in the Inuit population of Nunavik, Quebec, Canada
by: P De Wals, et al.
Published: (2019-01-01)